BACKGROUND: In 2002, the US National Heart, Lung, and Blood Institute (NHLBI) conducted a workshop to determine needs of the cell therapy community. A consensus emerged that improved access to cGMP facilities, regulatory assistance, and training would foster the advancement of cellular therapy. STUDY DESIGN AND METHODS: A 2003 NHLBI request for proposals resulted in four contracts being awarded to three cell-manufacturing facilities (Baylor College of Medicine, University of Minnesota, and University of Pittsburgh) and one administrative center (The EMMES Corporation). As a result, Production Assistance for Cellular Therapies (PACT) was formed. RESULTS: As of October 1, 2008, PACT has received 65 preliminary applications of which 45 have been approved for product manufacture. A variety of cell therapies are represented including T-regulatory cells, natural killer cells, adipose-derived stem cells, cardiac progenitor cells for cardiac disease, hematopoietic progenitor cells (HPCs) for central nervous system applications, cytotoxic T lymphocytes, and dendritic cells. A total of 169 products have been administered under 12 applications and 2 reagents were manufactured and delivered. Fourteen peer-reviewed publications and 15 abstracts have resulted from the PACT project to date. A cell therapy textbook is nearly complete. PACT technical projects have addressed assay development, rapid endotoxin testing, shipping of cell products, and CD34+ HPC isolation from low-volume marrow. Educational Web seminars and on-site training through workshops have been conducted. CONCLUSIONS: PACT is an active and successful cell therapy manufacturing resource in the United States, addressing research and training while forging relationships among academia, industry, and participating institutions.
BACKGROUND: In 2002, the US National Heart, Lung, and Blood Institute (NHLBI) conducted a workshop to determine needs of the cell therapy community. A consensus emerged that improved access to cGMP facilities, regulatory assistance, and training would foster the advancement of cellular therapy. STUDY DESIGN AND METHODS: A 2003 NHLBI request for proposals resulted in four contracts being awarded to three cell-manufacturing facilities (Baylor College of Medicine, University of Minnesota, and University of Pittsburgh) and one administrative center (The EMMES Corporation). As a result, Production Assistance for Cellular Therapies (PACT) was formed. RESULTS: As of October 1, 2008, PACT has received 65 preliminary applications of which 45 have been approved for product manufacture. A variety of cell therapies are represented including T-regulatory cells, natural killer cells, adipose-derived stem cells, cardiac progenitor cells for cardiac disease, hematopoietic progenitor cells (HPCs) for central nervous system applications, cytotoxic T lymphocytes, and dendritic cells. A total of 169 products have been administered under 12 applications and 2 reagents were manufactured and delivered. Fourteen peer-reviewed publications and 15 abstracts have resulted from the PACT project to date. A cell therapy textbook is nearly complete. PACT technical projects have addressed assay development, rapid endotoxin testing, shipping of cell products, and CD34+ HPC isolation from low-volume marrow. Educational Web seminars and on-site training through workshops have been conducted. CONCLUSIONS:PACT is an active and successful cell therapy manufacturing resource in the United States, addressing research and training while forging relationships among academia, industry, and participating institutions.
Authors: Ann M Leen; Uluhan Sili; Barbara Savoldo; Alan M Jewell; Pedro A Piedra; Malcolm K Brenner; Cliona M Rooney Journal: Blood Date: 2003-10-02 Impact factor: 22.113
Authors: Jeffery S Miller; Sarah Cooley; Peter Parham; Sherif S Farag; Michael R Verneris; Karina L McQueen; Lisbeth A Guethlein; Elizabeth A Trachtenberg; Michael Haagenson; Mary M Horowitz; John P Klein; Daniel J Weisdorf Journal: Blood Date: 2007-02-22 Impact factor: 22.113
Authors: David H McKenna; Darin Sumstad; Nancy Bostrom; Diane M Kadidlo; Susan Fautsch; Sarah McNearney; Rose Dewaard; Philip B McGlave; Daniel J Weisdorf; John E Wagner; Jeffrey McCullough; Jeffrey S Miller Journal: Transfusion Date: 2007-03 Impact factor: 3.157
Authors: A M Leen; G D Myers; C M Bollard; M H Huls; U Sili; A P Gee; H E Heslop; C M Rooney Journal: Ann N Y Acad Sci Date: 2005-12 Impact factor: 5.691
Authors: Theresa L Whiteside; Paolo Piazza; Amanda Reiter; Joanna Stanson; Nancy C Connolly; Charles R Rinaldo; Sharon A Riddler Journal: Clin Vaccine Immunol Date: 2008-11-26
Authors: Hans Klingemann; Carrie Grodman; Elliott Cutler; Marvin Duque; Diane Kadidlo; Andreas K Klein; Kellie A Sprague; Kenneth B Miller; Raymond L Comenzo; Tarun Kewalramani; Neng Yu; Richard A Van Etten; David H McKenna Journal: Transfusion Date: 2012-06-28 Impact factor: 3.157
Authors: Deborah Wood; Robin Wesselschmidt; Peiman Hematti; Adrian P Gee; Cliona Rooney; Leslie Silberstein; Myriam Armant; Larry Couture; John E Wagner; David H McKenna; Derek Hei; Traci Heath Mondoro; Lisbeth Welniak; Robert Lindblad Journal: Clin Transl Sci Date: 2014-03-21 Impact factor: 4.689
Authors: Fernanda F Cruz; Zachary D Borg; Meagan Goodwin; Dino Sokocevic; Darcy Wagner; David H McKenna; Patricia R M Rocco; Daniel J Weiss Journal: Stem Cells Transl Med Date: 2015-04-29 Impact factor: 6.940
Authors: Fernanda F Cruz; Zachary D Borg; Meagan Goodwin; Dino Sokocevic; Darcy E Wagner; Amy Coffey; Mariana Antunes; Kristen L Robinson; S Alex Mitsialis; Stella Kourembanas; Kristen Thane; Andrew M Hoffman; David H McKenna; Patricia R M Rocco; Daniel J Weiss Journal: Stem Cells Transl Med Date: 2015-09-16 Impact factor: 6.940
Authors: Fernanda F Cruz; Zachary D Borg; Meagan Goodwin; Amy L Coffey; Darcy E Wagner; Patricia R M Rocco; Daniel J Weiss Journal: Stem Cells Transl Med Date: 2016-03-01 Impact factor: 6.940